Home Online Features U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)
U.S. FDA approves Celltrion’s STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)
Hand-out
Press Releases
Celltrion  
December 18, 2024

U.S. FDA approves Celltrion’s STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)

STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn's disease (CD) and ulcerative colitis

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social